Mutation D816V alters the internal structure and dynamics of C-Kit receptor cytoplasmic region: Implications for dimerization and activation mechanisms

PLoS Computational Biology

Volumn 7, Issue 6, 2011, Pages

  Laine, Elodie ^a   de Beauchêne, Isaure Chauvot ^a   Perahia, David ^a   Auclair, Christian ^a   Tchertanov, Luba ^a  

^a Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BINDING SITES; CHEMICAL ACTIVATION; CONFORMATIONS; DIMERIZATION; DISEASES; ENZYMES; FREE ENERGY;

ACTIVATION MECHANISMS; CYTOPLASMIC REGIONS; DIMERIZATIONS; DYNAMICS SIMULATION; INTERNAL DYNAMICS; INTERNAL STRUCTURE; KINASE DOMAINS; NORMAL MODE ANALYSIS; STRUCTURE AND DYNAMICS; WILD TYPES;

MOLECULAR DYNAMICS;

PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOPLASM; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; GENE MUTATION; LIGAND BINDING; MOLECULAR DYNAMICS; MUTANT; MUTATIONAL ANALYSIS; PREDICTION; PROTEIN DOMAIN; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; THERMODYNAMICS; WILD TYPE; CHEMISTRY; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MUTATION; PRINCIPAL COMPONENT ANALYSIS;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DIMERIZATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PIPERAZINES; PRINCIPAL COMPONENT ANALYSIS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THERMODYNAMICS;

EID: 79959833426     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002068     Document Type: Article

References (115)

1. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635-648.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002) The protein kinase complement of the human genome. Science 298: 1912-1934.
3. Manning G, Plowman GD, Hunter T, Sudarsanam S, (2002) Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 27: 514-520.
4. Hunter T, Plowman GD, (1997) The protein kinases of budding yeast: six score and more. Trends Biochem Sci 22: 18-22.
5. Hanks SK, Hunter T, (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576-596.
6. Arock M, Valent P, (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 3: 497-516.
7. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, et al. (1988) Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7: 1003-1011.
8. Lemmon MA, Schlessinger J, (2010) Cell Signaling by Receptor Tyrosine Kinases. Cell 141: 1117-1134.
9. Yarden Y, Kuang WJ, Yangfeng T, Coussens L, Munemitsu S, et al. (1987) Human Protooncogene C-Kit- A New Cell-Surface Receptor Tyrosine Kinase for An Unidentified Ligand. EMBO J 6: 3341-3351.
10. Edling CE, Hallberg B, (2007) c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 39: 1995-1998.
11. Roskoski R, (2005) Structure and regulation of Kit protein-tyrosine kinase- The stem cell factor receptor. Bioch Biophys Res Commun 338: 1307-1315.
12. Craig AWB, Cosentino GP, Donze O, Sonenberg N, (1996) The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L. J Biol Chem 271: 24526-24533.
13. Ullrich A, Schlessinger J, (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
14. Liu H, Chen X, Focia PJ, He X, (2007) Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J 26: 891-901.
15. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, et al. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130: 323-334.
16. Weiss A, Schlessinger J, (1998) Switching signals on or off by receptor dimerization. Cell 94: 277-280.
17. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
18. Ashman LK, (1999) The biology of stem cell factor and its receptor C-kit. International J Biochem Cell Biol 31: 1037-1051.
19. Huse M, Kuriyan J, (2002) The conformational plasticity of protein kinases. Cell 109: 275-282.
20. Nolen B, Taylor S, Ghosh G, (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15: 661-675.
21. Griffith J, Black J, Faerman C, Swenson L, Wynn M, et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13: 169-178.
22. Hunter T, (2000) Signaling- 2000 and beyond. Cell 100: 113-127.
23. Hunter T, (1995) Protein-Kinases and Phosphatases- the Yin and Yang of Protein-Phosphorylation and Signaling. Cell 80: 225-236.
24. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, et al. (1995) W/Kit Gene Required for Interstitial-Cells of Cajal and for Intestinal Pacemaker Activity. Nature 373: 347-349.
25. Kitamura Y, Go S, (1979) Decreased Production of Mast-Cells in S1-S1D Anemic Mice. Blood 53: 492-497.
26. Kitamura Y, Shimada M, Go S, Matsuda H, Hatanaka K, et al. (1979) Distribution of Mast-Cell Precursors in Hematopoietic and Lymphopoietic Tissues of Mice. J Exp Med 150: 482-490.
27. Kitamura Y, Go S, Hatanaka K, (1978) Decrease of Mast-Cells in W-W Nu Mice and Their Increase by Bone-Marrow Transplantation. Blood 52: 447-452.
28. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R, (2005) Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 16-43.
29. Kitamura Y, Hirotab S, (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61: 2924-2931.
30. Miettinen M, Majidi M, Lasota J, (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38: S39-S51.
31. Levis M, Small D, (2003) FLT3: ITDoes matter in leukemia. Leukemia 17: 1738-1752.
32. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, et al. (1993) Identification of Mutations in the Coding Sequence of the Protooncogene C-Kit in A Human Mast-Cell Leukemia-Cell Line Causing Ligand-Independent Activation of C-Kit Product. J Clin Invest 92: 1736-1744.
33. Holst VA, Marshall CE, Moskaluk CA, Frierson HF, (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12: 956-960.
34. Forbes S, Clements J, Dawson E, Bamford S, Webb T, et al. (2006) Cosmic 2005. Br J Cancer 94: 318-322.
35. Maleddu A, Pantaleo MA, Nannini M, Di BM, Saponara M, et al. (2009) Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 21: 1359-1366.
36. Longley BJ, Reguera MJ, Ma Y, (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25: 571-576.
37. Fukuda R, Hamamoto N, Uchida Y, Furuta K, Katsube T, et al. (2001) Gastrointestinal stromal tumor with a novel mutation of KIT proto-oncogene. Int Med 40: 301-303.
38. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, et al. (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-798.
39. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439.
40. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, et al. (2003) Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278: 31461-31464.
41. Torrent M, Rickert K, Pan BS, Sepp-Lorenzino L, (2004) Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. J Mol Graph Model 23: 153-165.
42. Chian RJ, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, et al. (2001) Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 98: 1365-1373.
43. Bougherara H, Subra F, Crepin R, Tauc P, Auclair C, et al. (2009) The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 7: 1525-1533.
44. Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, et al. (1999) Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 93: 1319-1329.
45. Kannan N, Neuwald AF, (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351: 956-972.
46. Kornev AP, Taylor SS, Ten Eyck LF, (2008) A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A 105: 14377-14382.
47. Grant BJ, Gorfe AA, McCammon JA, (2010) Large conformational changes in proteins: signaling and other functions. Curr Opin Struct Biol 20: 142-147.
48. Laine E, Goncalves C, Karst JC, Lesnard A, Rault S, et al. (2010) Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc Natl Acad Sci U S A 107: 11277-11282.
49. Lee GM, Craik CS, (2009) Trapping moving targets with small molecules. Science 324: 213-215.
50. Banavali NK, Roux B, (2005) The N-terminal end of the catalytic domain of SRC kinase Hck is a conformational switch implicated in long-range allosteric regulation. Structure 13: 1715-1723.
51. Banavali NK, Roux B, (2007) Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck. Proteins 67: 1096-1112.
52. Banavali NK, Roux B, (2009) Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Proteins 74: 378-389.
53. Kastner J, Loeffler HH, Roberts SK, Martin-Fernandez ML, Winn MD, (2009) Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol 167: 117-128.
54. Lu T, Tan H, Lee D, Chen G, Jia Z, (2009) New insights into the activation of Escherichia coli tyrosine kinase revealed by molecular dynamics simulation and biochemical analysis. Biochemistry 48: 7986-7995.
55. Dixit A, Verkhivker GM, (2009) Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations. PLoS Comput Biol 5: e1000487.
56. Dixit A, Torkamani A, Schork NJ, Verkhivker G, (2009) Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96: 858-874.
57. Liu B, Bernard B, Wu JH, (2006) Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins 65: 331-346.
58. Bakan A, Bahar I, (2009) The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding. Proc Natl Acad Sci U S A 106: 14349-14354.
59. Cavasotto CN, Kovacs JA, Abagyan RA, (2005) Representing receptor flexibility in ligand docking through relevant normal modes. J Am Chem Soc 127: 9632-9640.
60. May A, Zacharias M, (2008) Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking. J Med Chem 51: 3499-3506.
61. Tobi D, Bahar I, (2005) Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci U S A 102: 18908-18913.
62. Cheng S, Niv MY, (2010) Molecular Dynamics Simulations and Elastic Network Analysis of Protein Kinase B (Akt/PKB) Inactivation. J Chem Inf Model 50: 1602-1610.
63. Vendome J, Letard S, Martin F, Svinarchuk F, Dubreuil P, et al. (2005) Molecular modeling of wild-type and D816V c-kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 48: 6194-6201.
64. Foster R, Griffith R, Ferrao P, Ashman L, (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23: 139-152.
65. Crespo A, Fernandez A, (2008) Induced disorder in protein-ligand complexes as a drug-design strategy. Mol Pharm 5: 430-437.
66. Fernandez A, Sanguino A, Peng Z, Crespo A, Ozturk E, et al. (2007) Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res 67: 4028-4033.
67. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A 106: 1542-1547.
68. Zou J, Wang YD, Ma FX, Xiang ML, Shi B, et al. (2008) Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 72: 323-332.
69. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663.
70. DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, et al. (2010) Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. J Biochem 147: 601-609.
71. Lyman E, Zuckerman DM, (2006) Ensemble-based convergence analysis of biomolecular trajectories. Biophys J 91: 164-172.
72. Laine E, Yoneda JD, Blondel A, Malliavin TE, (2008) The conformational plasticity of calmodulin upon calcium complexation gives a model of its interaction with the oedema factor of Bacillus anthracis. Proteins 71: 1813-1829.
73. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH, et al. (2000) Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
74. Straatsma TP, Berendsen HJC, Stam AJ, (1986) Estimation of statistical errors in molecular simulation calculations. Mol Phys 57: 89-95.
75. Blondel A, (2004) Ensemble variance in free energy calculations by thermodynamic integration: theory, optimal "Alchemical" path, and practical solutions. J Comput Chem 25: 985-993.
76. Laine E, Martinez L, Blondel A, Malliavin TE, (2010) Activation of the edema factor of Bacillus anthracis by Calmodulin: evidence of an interplay between the EF-calmodulin interaction and calcium binding. Biophys J 99: 2264-2272.
77. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, et al. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283: 18292-18302.
78. Batista PR, Robert CH, Marechal JD, Hamida-Rebai MB, Pascutti PG, et al. (2010) Consensus modes, a robust description of protein collective motions from multiple-minima normal mode analysis-application to the HIV-1 protease. Phys Chem Chem Phys 12: 2850-2859.
79. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, et al. (2009) Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One 4: e7485.
80. Xie P, Streu C, Qin J, Bregman H, Pagano N, et al. (2009) The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 48: 5187-5198.
81. Bae JH, Schlessinger J, (2010) Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol Cells 29: 443-448.
82. Bae JH, Boggon TJ, Tome F, Mandiyan V, Lax I, et al. (2010) Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci U S A 107: 2866-2871.
83. Aleksandrov A, Simonson T, (2010) Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem 285: 13807-13815.
84. Kabsch W, Sander C, (1983) Dictionary of Protein Secondary Structure- Pattern-Recognition of Hydrogen-Bonded and Geometrical Features. Biopolymers 22: 2577-2637.
85. Cuff JA, Barton GJ, (2000) Application of multiple sequence alignment profiles to improve protein secondary structure prediction. Proteins Struct Funct Genet 40: 502-511.
86. Mcdonald IK, Thornton JM, (1994) Satisfying Hydrogen-Bonding Potential in Proteins. J Mol Biol 238: 777-793.
87. DeLano WL, (2002) The PyMOL Molecular Grapics System, Delano Scientific, San Carlos, CA, USA.
88. Bohacek RS, Mcmartin C, (1992) Definition and Display of Steric, Hydrophobic, and Hydrogen-Bonding Properties of Ligand-Binding Sites in Proteins Using Lee and Richards Accessible Surface- Validation of A High-Resolution Graphical Tool for Drug Design. J Med Chem 35: 1671-1684.
89. Sarkhel S, Desiraju GR, (2004) N- H...O, O- H...O, and C- H...O hydrogen bonds in protein-ligand complexes: Strong and weak interactions in molecular recognition. Proteins Struct Funct Genet 54: 247-259.
90. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucl Acids Res 28: 235-242.
91. Fiser A, Do RKG, Sali A, (2000) Modeling of loops in protein structures. Protein Science 9: 1753-1773.
92. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325.
93. Ponder JW, Case DA, (2003) Force fields for protein simulations. Adv Protein Chem 66: 27-85.
94. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
95. Jorgensen WL, Jenson C, (1998) Temperature dependence of TIP3P, SPC, and TIP4P water from NPT Monte Carlo simulations: Seeking temperatures of maximum density. J Comput Chem 19: 1179-1186.
96. Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR, (1984) Molecular-Dynamics with Coupling to An External Bath. J Chem Phys 81: 3684-3690.
97. Loncharich RJ, Brooks BR, Pastor RW, (1992) Langevin Dynamics of Peptides- the Frictional Dependence of Isomerization Rates of N-Acetylalanyl-N'-Methylamide. Biopolymers 32: 523-535.
98. Darden T, York D, Pedersen L, (1993) Particle Mesh Ewald- An N.Log(N) Method for Ewald Sums in Large Systems. J Chem Phys 98: 10089-10092.
99. Sanner MF, Olson AJ, Spehner JC, (1996) Reduced surface: An efficient way to compute molecular surfaces. Biopolymers 38: 305-320.
100. Wallace AC, Laskowski RA, Thornton JM, (1995) Ligplot- A Program to Generate Schematic Diagrams of Protein Ligand Interactions. Protein Eng 8: 127-134.
101. Humphrey W, Dalke A, Schulten K, (1996) VMD: Visual molecular dynamics. J Mol Graph 14: 33-38.
102. Gentleman R, Ihaka R, (2000) Lexical scope and statistical computing. J Comput Graph Stat 9: 491-508.
103. Bashford D, Case DA, (2000) Generalized born models of macromolecular solvation effects. Annu Rev Phys Chem 51: 129-152.
104. Onufriev A, Bashford D, Case DA, (2000) Modification of the generalized Born model suitable for macromolecules. J Phys Chem B 104: 3712-3720.
105. Onufriev A, Bashford D, Case DA, (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55: 383-394 DOI 10.1002/prot.20033.
106. Perahia D, Mouawad L, (1995) Computation of low-frequency normal modes in macromolecules: improvements to the method of diagonalization in a mixed basis and application to hemoglobin. J Comput Chem 19: 241-246.
107. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) Charmm- A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J Comput Chem 4: 187-217.
108. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, et al. (2009) CHARMM: The Biomolecular Simulation Program. J Comput Chem 30: 1545-1614.
109. Tama F, Sanejouand YH, (2001) Conformational change of proteins arising from normal mode calculations. Protein Eng 14: 1-6.
110. Bruschweiler R, (1995) Collective Protein Dynamics and Nuclear-Spin Relaxation. J Chem Phys 102: 3396-3403.
111. Floquet N, Marechal JD, Badet-Denisot MA, Robert CH, Dauchez M, et al. (2006) Normal mode analysis as a prerequisite for drug design: application to matrix metalloproteinases inhibitors. FEBS Lett 580: 5130-5136.
112. Floquet N, Durand P, Maigret B, Badet B, Badet-Denisot MA, et al. (2009) Collective motions in glucosamine-6-phosphate synthase: influence of ligand binding and role in ammonia channelling and opening of the fructose-6-phosphate binding site. J Mol Biol 385: 653-664.
113. Le GV, Schmidtke P, Tuffery P, (2009) Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10: 168.
114. Schmidtke P, Souaille C, Estienne F, Baurin N, Kroemer RT, (2010) Large-Scale Comparison of Four Binding Site Detection Algorithms. J Chem Inf Model.
115. Lyskov S, Gray JJ, (2008) The RosettaDock server for local protein-protein docking. Nucl Acids Res 36: W233-W238.